There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GM-CSF


GM-CSF Molecule Information

Name:Macrophage colony stimulating factor 2
Target Synonym:Molgramostin;CSF2;GM-CSF;GMCSF;Granulocyte-macrophage colony-stimulating factor;Colony-stimulating factor;CSF;Sargramostim
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Phase ?

GM-CSF Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
Cat. No. Species Product Description Structure Purity Feature
GMF-H8214 Human Biotinylated Human GM-CSF, epitope tag free, ultra sensitivity (primary amine labeling)
GMF-H4214 Human ActiveMax® Human GM-CSF Protein, Tag Free

GM-CSF Part of Bioactivity data

GMF-H4214-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

The bio-activity was determined by dose-dependent stimulation of the proliferation of TF-1 cells. The ED50 < 0.1 ng/mL, corresponding to a specific activity of > 1x107 Unit/mg.


Loaded Biotinylated Human GM-CSF, epitope tag free, primary amine labeling (Cat. No. GMF-H8214) on SA Biosensor, can bind Human GM-CSF R alpha, His Tag (SPR verified) (Cat. No. GRA-H52H7) with an affinity constant of 23.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human GM-CSF R alpha, Fc Tag (Cat. No. GRA-H5255) on Protein A Biosensor, can bind ActiveMax® Human GM-CSF, Tag Free (Cat. No. GMF-H4214) with an affinity constant of 9.21 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

GM-CSF Molecule Synonym Name


GM-CSF Molecule Background

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.

GM-CSF References

GM-CSF Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Namilumab AMG-203; Amg-203; IZN-101; MT-203 Phase Ⅱ Amgen, Takeda, Izana Bioscience Ankylosing Spondylitis (AS), Plaque psoriasis, Rheumatoid arthritis (RA) Details
Attenuated viral vector immunogene-based therapy and vaccine (Radient Pharmaceuticals) Phase Ⅰ Radient, Jaiva Technologies Cancer Details
Plasmid cDNA vaccine (Colby Pharmaceutical) Phase Ⅰ Colby Prostate cancer Details
GM-CSF cell therapy (University of Wisconsin) Phase Ⅰ University of Wisconsin-Madison Melanoma Details
TJ-003234 TJ-003234; TJ-003234RAR101; TJM-2,TJ003234,TJM2 Phase Ⅱ I-MAB Biopharma Coronavirus Disease 2019 (COVID-19) Details
Lenzilumab KB-003 Phase Ⅲ KaloBios Coronavirus Disease 2019 (COVID-19) Details
Pancreatic cancer immunotherapy (Cell Genesys) Phase Ⅱ Cell Genesys Pancreatic cancer Details
Gimsilumab MORAb-022 Phase Ⅱ Morphotek Nasopharyngeal cancer Details
Otilimab GSK-3196165; MOR-103; MOR-04357; GSK-165 Phase Ⅲ University of Melbourne, GlaxoSmithKline, MorphoSys Rheumatoid arthritis (RA) Details
PBI-1402 PBI-1402 Phase Ⅱ Prometic Life Sciences, Shanghai Allist Pharmaceuticals Anemia Details
PD-360324 PD-360324; PD-0360324 Phase Ⅱ Pfizer Solid tumours Details

This web search service is supported by Google Inc.